Japan's Takeda eyes new focus on vaccines after OTC asset sales-CEO > 문의게시판

본문 바로가기

웰빙 놀이공간을 만드는 플레이123

어린이들이 안전하게 뛰어놀 수 있는 놀이공간을 만들기 위해 노력하겠습니다.

문의게시판

Japan's Takeda eyes new focus on vaccines after OTC asset sales-CEO

페이지 정보

작성자 Darcy 작성일23-11-08 15:13 조회13회 댓글0건

본문

By Rocky Swift

TOKYO, Nov 6 (Reuters) - Japan's Takeda Pharmaceutical Co is looking at making vaccines clomid without a prescription core business after completing asset sales to lower debt following its takeover of Shire Plc, Chief Executive Christophe Weber said.

Japan's biggest drugmaker by revenue recently completed $10 billion in sales of mostly over-the-counter drug assets to reduce debt after its $59 billion purchase of Shire, saying it would focus on five key business areas.

With a dengue fever vaccine in development and deals to make and distribute COVID-19 vaccines in Japan, the company could add a new pillar to its business lineup, Weber said.

"We are in the vaccines business," Weber told Reuters in an interview. "If the dengue vaccine is successful, yes, it would be clomid without a prescription sixth one."

Takeda's current five core businesses are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

The company looked into making a COVID-19 vaccine, but determined with its mix of technology and capacity, it was a better fit to work with other developers, Weber said.

Takeda agreed last month to distribute 50 million doses of Moderna Inc's COVID-19 vaccine in Japan. That was on top of a previous deal to produce Novavax Inc's COVID-19 candidate, aiming to make 250 million doses.

Takeda's dengue vaccine candidate, TAK-003, is on track for regulatory filing in Asia, Latin America, and the European Union by the end of fiscal 2020, the company said last month. The disease is spread by mosquitoes and is estimated to affect 50 million people a year worldwide with 22,000 deaths.

Following the Shire takeover, Takeda reached its asset disposal goal with the sale of its Japanese consumer healthcare business to Blackstone Group for 242 billion yen ($2.31 billion) announced in August.

The company was not eyeing any more major sell offs, Weber said, saying any such deals would be "very marginal." (Reporting by Rocky Swift; editing by Jane Wardell)

If you have any concerns with regards to wherever and how to use clomid without dr prescription, you can speak to us at the web site.

댓글목록

등록된 댓글이 없습니다.

플레이123


회사명 : 플레이123     I     대표 김익태     I     사업자등록번호 306-03-54609
사무실 : 대전광역시 유성구 유성대로 654번길 16 (구암동 625-2)
TEL : 1899-1742 FAX : 042-822-4938
창고 : 청주시 서원구 남이면 부용외천2길 13-23 (부용외천리 127-2)

하나은행 661-910216-05507 예금주 : 김익태(플레이123)
플레이123의 모든 이미지 및 컨텐츠 저작권은 무단사용을 금합니다.
Contact Us

1899-1742
상담시간: AM 10:00 ~ PM 06:00
일요일, 공휴일 휴무
담당자 : 010-5123-8628
이메일 : gunicadj@naver.com